1-4 of 4
Changyong Hu
Close
Sort by
Journal Articles

SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Kee C. Goh, Wai C. Ong, Changyong Hu, Hannes Hentze, Ai L. Liang, Walter Stunkel, Yong C. Tan, Kanda Sangthongpitag, Siok K. Goh, Shirly Sieh, Zahid Q. Bonday, Anthony D. William, Angeline Lee, Stephanie Blanchard, Te C. Liu, Martin Sattler, James D. Griffin, Brian W. Dymock, Ethirajulu Kantharaj, Jeanette M. Wood
Journal: Blood
Blood (2007) 110 (11): 538.
https://doi.org/10.1182/blood.V110.11.538.538
Published: 2007
Journal Articles

Pharmacokinetic and Pharmacodynamic Properties of SB1317, a Potent and Orally Active Multi-Kinase Inhibitor.

Pauline Yeo, P. Venkatesh, Evelyn Goh, Peizi Zeng, Lee S. New, Changyong Hu, Kanda Sangthongpitag, Anthony D. William, Kee C. Goh, Jeanette M. Wood, Ethirajulu Kantharaj
Journal: Blood
Blood (2007) 110 (11): 4201.
https://doi.org/10.1182/blood.V110.11.4201.4201
Published: 2007
Journal Articles

SB1317, a Potent and Orally Active FLT3-CDK Inhibitor with High Anti-Tumor Efficacy in Models of Hematological Malignancies.

Kee C. Goh, PhD, Wai C. Ong, BSc, Changyong Hu, MD, PhD, Ai L. Liang, BSc, Walter Stunkel, PhD, Yong C. Tan, MSc, Kanda Sangthongpitag, PhD, Siok K. Goh, BSc, Zahid Q. Bonday, PhD, Anthony D. William, PhD, Brian W. Dymock, PhD, Ethirajulu Kantharaj, PhD, Jeanette M. Wood, PhD
Journal: Blood
Blood (2007) 110 (11): 1593.
https://doi.org/10.1182/blood.V110.11.1593.1593
Published: 2007
Journal Articles

SB939: A Potent and Orally Active HDAC Inhibitor for the Treatment of Hematological Malignancies.

Kanda Sangthongpitag, Walter Stunkel, Zahid Q. Bonday, Kee C. Goh, Xukun Wang, Xiaofeng Wu, Changyong Hu, Haishan Wang, Niefang Yu, Eric Sun, Michael Entzeroth, Ethirajulu Kantharaj, Chien-Shing Chen, Jeanette M. Wood
Journal: Blood
Blood (2007) 110 (11): 1603.
https://doi.org/10.1182/blood.V110.11.1603.1603
Published: 2007